Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

IDXX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

IDXX

AI Research Report

Powered by Claude

Ready to analyze IDXX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 20d (May 5)
IDEXX Laboratories Inc

IDEXX Laboratories Inc

Health Care·NASDAQ NMS - GLOBAL MARKET·US·IPO 1991-06-21
  • Yahoo·7h ago

    Is it a Prudent Move to Retain IDXX Stock in Your Portfolio Now?

    IDEXX rides on strong diagnostics growth and software momentum, but FX pressure and weak solvency cloud its outlook - should investors hold now?

  • Yahoo·11h ago

    These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

    Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

  • Yahoo·1d ago

    Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?

    Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Yahoo·1d ago

    IDEXX Laboratories Stock Up 39.4% in a Year: What's Driving It?

    IDXX stock surges over the past year, fueled by strong diagnostics growth, innovation traction and expanding global demand in pet healthcare markets.

  • Yahoo·3d ago

    IDEXX (IDXX) Launches Canine Cancer Detection Panel in UK

    IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the 9 Best QQQ Stocks to Buy Now. On April 01, IDEXX Laboratories announced the launch of the IDEXX Cancer Dx Panel in the UK, specifically for the early detection of lymphoma in at-risk dogs. This blood-based test is designed to integrate into both sick-pet diagnostics and routine […]

  • Yahoo·4d ago

    Is This the Right Time to Add Globus Medical Stock to Your Portfolio?

    GMED rides on NuVasive synergies, strong cash flow and rapid innovation, but macro pressures and rising costs cloud its near-term outlook.

  • Yahoo·4d ago

    Thermo Fisher Stock May Benefit Following Collaboration With PRECISE

    TMO teams up with PRECISE on a major proteomics study, expanding its role in large biobank projects and precision medicine initiatives.

  • Yahoo·4d ago

    NEOG Q3 Earnings & Revenues Top, Gross Margin Down, Stock Crashes

    Neogen beats Q3 earnings and revenue estimates, but margins slump and stock drops nearly 3% after results.

  • View all news →

Recent insider activity

View all →
  • 4FORM 4
    Mar 5
  • 4FORM 4
    Mar 5
  • 4/AFORM 4/A
    Mar 3
  • 4FORM 4
    Mar 2
  • 4FORM 4
    Feb 27

Factor Grades

View details →
C+
Overall score: 58/100
D-
Valuation
B-
Growth
A
Profitability
D+
Momentum
B
Financial Health
NASDAQ NMS - GLOBAL MARKETMarket closed
IDEXX Laboratories Inc
Health Care
$584.05
$10.05 (+1.75%)
Open
$573.15
Prev close
$574.00
Day range
$571.07 – $585.74
52W range
$372.32 – $769.98
Mkt cap
$46.39B
P/E
43.7
EPS
$13.08
Beta
1.69

Fundamentals

Valuation
Market Cap
$46.39B
P/E (TTM)
43.65S&P avg ~22
P/S (TTM)
10.75S&P avg ~2.8
P/B
33.65S&P avg ~4.5
P/FCF
44.32S&P avg ~26
EPS (TTM)
$13.08
Book/sh
$20.14
Cash/sh
$2.26
Profitability
Gross Margin
61.80%avg ~45%
Operating Margin
31.60%avg ~15%
Net Margin
24.62%avg ~12%
ROE
69.78%avg ~18%
ROA
31.91%avg ~7%
ROI
42.61%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
10.42%
Rev Growth 5Y
9.72%
EPS Growth YoY
22.64%
EPS Growth 5Y
14.28%
Current Ratio
—
Quick Ratio
0.85
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.69
52W High
$769.98
52W Low
$372.32
Avg Vol (10D)
557.6K
Avg Vol (3M)
516.7K
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (22)
Price Performance
5D-0.14%
MTD+2.16%
3M-19.43%
6M-8.57%
YTD-15.16%
1Y+50.33%

Analyst Consensus

Buy
Based on 22 analysts
Period: 2026-04-01
16 Buy (73%)6 Hold (27%)0 Sell (0%)
Rating Distribution
Strong Buy
7
Buy
9
Hold
6
Sell
0
Strong Sell
0
Trend
2026-04
16/6/0
2026-03
16/6/0
2026-02
16/6/0
2026-01
16/6/0